Infinity Pharmaceuticals Stock Working Capital
| INFIDelisted Stock | USD 0.13 0.01 7.14% |
Infinity Pharmaceuticals fundamentals help investors to digest information that contributes to Infinity Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Infinity Stock. The fundamental analysis module provides a way to measure Infinity Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Infinity Pharmaceuticals stock.
Infinity |
Infinity Pharmaceuticals Company Working Capital Analysis
Infinity Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Infinity Pharmaceuticals Working Capital | 26.67 M |
Most of Infinity Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infinity Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Infinity Pharmaceuticals has a Working Capital of 26.67 M. This is 93.73% lower than that of the Biotechnology sector and 95.05% lower than that of the Health Care industry. The working capital for all United States stocks is 98.2% higher than that of the company.
Infinity Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infinity Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infinity Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Infinity Pharmaceuticals by comparing valuation metrics of similar companies.Infinity Pharmaceuticals is currently under evaluation in working capital category among its peers.
Infinity Fundamentals
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X | |||
| Price To Sales | 19.29 X | |||
| Revenue | 2.59 M | |||
| Gross Profit | (31.38 M) | |||
| EBITDA | (44.84 M) | |||
| Net Income | (44.37 M) | |||
| Cash And Equivalents | 56.58 M | |||
| Cash Per Share | 0.63 X | |||
| Total Debt | 917 K | |||
| Debt To Equity | 0.13 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | (0.41) X | |||
| Cash Flow From Operations | (42.43 M) | |||
| Short Ratio | 0.31 X | |||
| Earnings Per Share | (0.45) X | |||
| Price To Earnings To Growth | (0.05) X | |||
| Target Price | 0.3 | |||
| Number Of Employees | 30 | |||
| Beta | 1.38 | |||
| Market Capitalization | 2.63 M | |||
| Total Asset | 42.15 M | |||
| Retained Earnings | (855.95 M) | |||
| Working Capital | 26.67 M | |||
| Current Asset | 254.7 M | |||
| Current Liabilities | 70.06 M | |||
| Z Score | -29.4 | |||
| Net Asset | 42.15 M |
About Infinity Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Infinity Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infinity Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infinity Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |